Objectives: Antimicrobial lock solutions are used for prevention and management of catheter-related bloodstream infections. ML8-X10 (a prototype oil-in-water micro-emulsion based on a novel free fatty acid), vancomycin/heparin and taurolidine/citrate/heparin (Taurolock TM -Hep500) lock solutions were tested against biofilm-forming Staphylococcus epidermidis and methicillin-susceptible Staphylococcus aureus.
Introduction
Staphylococcal catheter infections are often caused by biofilmproducing strains, which are difficult to eradicate. Vancomycin is commonly used in a catheter lock solution in managing such infections. 1 Some free fatty acids have antithrombotic properties and antimicrobial activity against bacteria, yeast and viruses. 2 -4 ML8-X10 is a prototype, novel catheter lock solution under development. It is an aqueous-based emulsion of free fatty acid in lipid microspheres. We evaluated the activity of ML8-X10, vancomycin and taurolidine/citrate as catheter lock solutions against biofilmforming staphylococci in an in vitro central venous catheter (CVC) model.
Methods

Test organisms
Known biofilm-producing strains of Staphylococcus epidermidis (ATCC 35984) and Staphylococcus aureus (ATCC 35556) were evaluated.
Media
Strains were grown overnight on tryptic soy agar (TSA). Mueller -Hinton broth (MHB) supplemented with 25 mg/L calcium and 12.5 mg/L magnesium was used for MIC analysis and modified as noted below. Tryptic soy broth (TSB) supplemented with 25 mg/L calcium, 1% glucose and 2% sodium chloride was used to optimize biofilm formation. 
MIC
MICs and MBCs were determined in MHB. 5 The MICs were also determined in MHB acidified with the addition of hydrochloric acid to pH 5.0 since ML8-X10 activity is greatest at low pH and is known to drop off quickly above pH 5.0.
Antimicrobial activity in a catheter model
ML8-X10 (Marvao Medical, Inc., Ireland), 5 mg/mL vancomycin (Hospira, Lake Forest, IL, USA) plus preservative-containing (0.45% benzyl alcohol) 5000 U/mL heparin (Hospira) and 1.35% (cyclo)taurolidine with 4% citrate and 500 U/mL heparin (Taurolock TM -Hep500, TauroPharm GmbH, Germany) Figure 1 . Activity of antimicrobial lock solutions against S. epidermidis after 8, 24 or 72 h of exposure. Activity was measured as change (average and SEM) in log 10 cfu/mL from the 0 h timepoint for bacteria recovered from a 1 mL saline flush through the catheter segment ('flush', dark grey), from a cut catheter segment ('cut', light grey) and the combined total bacteria recovered ('total', white). ML8, ML8-X10; TLH, 1.35% taurolidine, 4% citrate and 500 U/mL heparin; VANH, 5 mg/mL vancomycin with 5000 U/mL heparin.
were evaluated in a multi-lumen polyurethane CVC [Arrow-Howes CVC w (MC-15703), Reading, PA, USA] model. 6 Device inoculation and treatment A 0.5 McFarland standard from overnight growth on TSA was diluted (1: 100) in TSB and added to the lumen of multi-lumen CVCs. Each lock solution was introduced after 24 h of biofilm development, based on previous studies. 7, 8 Broth was drained after 24 h of incubation and catheter lock solution sufficient to fill the catheter lumen was introduced. Since the catheter lock solution completely filled the lumen of the CVC, the pH of the experiment was that of the lock solution being tested.
Regimen simulations included ML8-X10 alone, 5 mg/mL vancomycin plus 5000 U/mL heparin (plus 0.45% benzyl alcohol) or 1.35% taurolidine plus 4% citrate plus 500 U/mL heparin. Catheters were clamped at the distal end as soon as the antimicrobial lock solution filled each lumen. Each system was then incubated at 358C for an additional 8, 24 or 72 h. Each organism was tested against each agent in triplicate.
Recovery of test organisms
At the endpoint, catheter luminal fluid was obtained by opening the clamps and draining the contents into a sterile test tube. A sterile needle was introduced into the open lumen of each access port and 1 mL of normal saline was flushed through the lumen and collected in a sterile test tube. To optimize yield of viable bacteria, the flushed saline was then sonicated at 60 W for 1 min, then vortexed for 15 s. Additionally, a 3 cm cut segment of each catheter was sonicated at 60 W for 1 min. A 100 mL volume of the flushed, sonicated saline and saline from the cut segment was serially diluted 10-fold and transferred to TSA plates, which were incubated overnight at 358C. The limit of detection for the flushed, sonicated and vortexed cultures from the access port and lumen and the sonicated saline of the catheter segment is 2.0 log 10 cfu/mL. Vacuum filtration was used to quantify bacterial counts as necessary with a limit of detection of 1.0 log 10 cfu/mL.
Data analysis
Statistical analyses were performed using SPSS software (release 20; SPSS, Inc., Chicago, IL, USA). Activity at 8, 24 or 72 h was compared for the catheter lock solutions using ANOVA followed by Tukey's post hoc test for multiple comparisons. 9 Results and discussion
MIC
Catheter lock solutions were active at the concentrations used in the catheter lock model ( Figure 2 . Activity of antimicrobial lock solutions against S. aureus after 8, 24 or 72 h of exposure. Activity was measured as change (average and SEM) in log 10 cfu/mL from the 0 h timepoint for bacteria recovered from a 1 mL saline flush through the catheter segment ('flush', dark grey), from a cut catheter segment ('cut', light grey) and the combined total bacteria recovered ('total', white). ML8, ML8-X10; TLH, 1.35% taurolidine, 4% citrate and 500 U/mL heparin; VANH, 5 mg/mL vancomycin with 5000 U/mL heparin.
Novel antimicrobial catheter lock solution 3265 JAC taurolidine plus citrate and heparin were enhanced at a lower pH (P,0.05). It is known that the activity of ML8-X10 is optimal at pH levels ,5.0.
Catheter lock model
Against S. epidermidis, total ML8-X10 activity was not significantly different from that of vancomycin, but it was less than that of taurolidine at 8 h (P, 0.001) (Figure 1 ). For the catheter lumen flush at 24 h, ML8-X10 was as active as taurolidine and vancomycin, but less active than taurolidine against the bacteria found in the cut catheter segment culture (P, 0.001). For the combined total bacterial counts of the flush and cut models, taurolidine was more active than ML8-X10 (P,0.001), which was more active than vancomycin (P ¼0.001). At 72 h, activity measured as colony counts of bacteria recovered from the catheter lumen flush and cut catheter segments was similar for all the lock solutions, approaching or meeting the limit of detection.
Against S. aureus, for the catheter lumen flush, ML8-X10 activity was not significantly different from taurolidine activity after 8 h; both were greater than vancomycin activity at 8 h (P, 0.001) (Figure 2 ). For bacteria recovered from the cut catheter segments, ML8-X10 activity was not significantly different from vancomycin activity, but lower than taurolidine activity at 8 h (P, 0.001). At 24 h, all lock solutions demonstrated similar activity against the bacteria recovered from catheter lumen flush. Bacterial counts recovered from the cut catheter segments and the overall counts recovered were similar. Taurolidine solution was the most active (P≤0.001) and activities of ML8-X10 and vancomycin were not significantly different. At 72 h, all lock solutions reduced colony counts to levels that approached or reached the limit of detection; however, taurolidine and vancomycin solutions were more active than ML8-X10 against the catheter lumen flush organisms (P≤ 0.04). The same was true for the total bacteria recovered, but no significant differences were found in activity of any of the lock solutions against the bacteria from the cut catheter segments.
We tested ML8-X10, a prototype oil-in-water emulsion, for potential use as an antimicrobial catheter lock solution. Antimicrobial activity of free fatty acids involves disruption of the electron transport chain and oxidative phosphorylation. 10 Naturally occurring free fatty acids have cis-oriented double bonds, which have greater antimicrobial activity. One example is cis-2-decenoic acid, which inhibits S. aureus growth and biofilm formation in addition to dispersing biofilm.
11 Taurolidine (1.35%) plus sodium citrate (4%) and heparin (500 U/mL) is a commercially available catheter lock solution in Europe, but not in the USA. Taurolidine-containing lock solutions are effective in the prevention 12 and treatment 13 of catheter-related bloodstream infections.
There are some limitations to our study. While the concentrations and dwell times of heparin and the taurolidine lock solution with citrate and heparin have been used in haemodialysis patients 14 with similar antithrombotic activity, the antithrombotic activity of ML8-X10 was not evaluated in our study. In addition, this study focused on antimicrobial activity in a pre-established CVC biofilm and we did not assess the potential utility of ML8-X10 as a prophylactic antimicrobial lock solution.
Conclusions
In conclusion, ML8-X10, taurolidine plus citrate and heparin, and vancomycin plus heparin were active against biofilm-forming staphylococci at the concentrations used in our CVC model. Taurolidine was more active than the other two lock solutions at 8 h. Activity was greatest at 72 h, where all lock solutions were highly active and reduced colony counts to levels that approached or reached the limit of detection. Our findings suggest that the antimicrobial activity of the taurolidine lock solution was more rapidly acting than the prototype ML8-X10 solution and the vancomycin lock solution, particularly against the adherent bacteria from the cut catheter segment. ML8-X10 demonstrated similar or greater activity than a vancomycin plus heparin lock solution and, based on our data, free fatty acid emulsions show promise as a new class of antimicrobial lock solution worthy of additional development and study.
